Previous studies had shown that people who regularly take nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are less likely to develop Parkinson’s disease. These results prompted the Mayo
Evotec’s EVT 101 is an NR2B subtype-specific NMDA receptor antagonist developed for the treatment of Alzheimer’s disease and/or neuropathic pain. A total of 90 healthy subjects, both young
Experiments conducted by the University of Texas Medical Branch (UTMB) scientists show that a SARS coronavirus protein called nsp1 causes the breakdown of biochemical messages that normally prompt
Clinical trial site initiations and the enrollment of women for the trial began in late July, after Third Wave came to an agreement with the FDA on the
The findings, published in the online edition of the Proceedings of the National Academy of Sciences, provide the basis for further development of a safe and effective treatment
NanoBio has developed multiple topical anti-infective products and vaccine candidates derived from its patented NanoStat technology platform. Products developed from the technology have a unique ability to penetrate
Major participating investors included Forward Ventures, Lilly Ventures, and Novo A/S. The funding will be used to advance the clinical development of Calsed (amrubicin hydrochloride), Cabrellis’ third-generation anthracycline,
The randomized, double-blind, placebo-controlled phase II trial is expected to enroll approximately 72 patients with pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD). The primary endpoint
Estrogen receptor-beta (ER-beta) agonists selectively bind and activate the ER-beta receptor. There are two forms of estrogen receptor: The first form of the receptor to be discovered was
The first of these agreements is focused on the development of methodologies to identify and quantify certain cell types circulating in blood that are potentially valuable biomarkers for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.